IDH2 and acute myeloid leukemia: Eegger’s test suggests there may be publication bias in the 2-year OS rate in newly diagnosed IDH-mutated AML patients treated with IDH inhibitors (p = 0.0432) and therefore should be interpreted cautiously in conjunction with other results.